ShortHER随机辅助试验中肿瘤浸润淋巴细胞与早期HER2阳性乳腺癌远处无病生存的关联
ShortHER辅助试验纳入866例早期HER2阳性乳腺癌患者,比较9周与1年曲妥珠单抗联合化疗。集中评估基质肿瘤浸润淋巴细胞(TILs),中位随访6.1年,TILs每增加10%与远处无病生存(DDFS)独立相关(HR 0.73,95%CI 0.59-0.89,P=0.006),且TILs与治疗臂存在交互作用(交互P=0.015)。
要点
- TILs每增加10%,DDFS独立改善(HR 0.73,95%CI 0.59-0.89,P=0.006)。
- 5年DDFS率:TILs<20%组91.1% vs TILs≥20%组95.7%(P=0.025)。
- TILs<20%时短疗程较长疗程HR 1.75(95%CI 1.09-2.80,P=0.021)。
核心结论
- TILs是接受辅助化疗联合曲妥珠单抗治疗的HER2阳性早期乳腺癌患者的独立预后因素,可能 refine 识别低复发风险、适合降阶梯辅助治疗患者的能力。
研究设计与样本
- ShortHER随机辅助试验,纳入866例早期HER2阳性乳腺癌患者,比较9周与1年曲妥珠单抗联合化疗,集中评估基质TILs。
- 中位随访6.1年。
主要发现
- TILs中位值为5%(Q1-Q3 1%-15%)。
- 多变量模型中,TILs每增加10%与更好的DDFS独立相关(HR 0.73,95%CI 0.59-0.89,P=0.006)。
- 5年DDFS率:TILs<20%组91.1% vs TILs≥20%组95.7%(P=0.025)。
- TILs每增加10%与DDFS的关联在随机分配至9周曲妥珠单抗组显著(HR 0.60,95%CI 0.41-0.88),在1年曲妥珠单抗组不显著(HR 0.89,95%CI 0.71-1.12;交互作用检验P=0.088)。
- TILs<20%患者中,短疗程 vs 长疗程的HR为1.75(95%CI 1.09-2.80,P=0.021);TILs≥20%患者中,短疗程 vs 长疗程的HR为0.23(95%CI 0.05-1.09,P=0.064),交互作用显著(P=0.015)。
临床怎么用
- 作者认为TILs可能 refine 识别低复发风险、适合降阶梯辅助治疗患者的能力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is the need to identify new prognostic markers to refine risk stratification for HER2-positive early breast cancer patients. The aim of this study was to evaluate the association of tumor-infiltrating lymphocytes (TILs) with distant disease-free survival (DDFS) in patients with HER2-positive early breast cancer enrolled in the ShortHER adjuvant trial which compared 9 weeks versus 1-year trastuzumab in addition to chemotherapy, and to test the interaction between TILs and treatment arm. PATIENTS AND METHODS: Stromal TILs were assessed for 866 cases on centralized hematoxylin and eosin-stained tumor slides. The association of TILs as 10% increments with DDFS was assessed with Cox models. Kaplan-Meier curves were estimated for patients with TILs ≥20% and TILs <20%. Median follow-up was 6.1 years. RESULTS: Median TILs was 5% (Q1-Q3 1%-15%). Increased TILs were independently associated with better DDFS in multivariable model [hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.59-0.89, P = 0.006, for each 10% TILs increment]. Five years DDFS rates were 91.1% for patients with TILs <20% and 95.7% for patients with TILs ≥20% (P = 0.025). The association between 10% TILs increments and DDFS was significant for patients randomized to 9 weeks of trastuzumab (HR 0.60, 95% CI 0.41-0.88) but not for patients treated with 1 year of trastuzumab (HR 0.89, 95% CI 0.71-1.12; test for interaction P = 0.088). For patients with TILs <20%, the HR for the comparison between the short versus the long arm was 1.75 (95% CI 1.09-2.80, P=0.021); whereas, for patients with TILs ≥20% the HR for the comparison of short versus long arm was 0.23 (95% CI 0.05-1.09, P = 0.064), resulting in a significant interaction (P = 0.015). CONCLUSIONS: TILs are an independent prognostic factor for HER2-positive early breast cancer patients treated with adjuvant chemotherapy and trastuzumab and may refine the ability to identify patients at low risk of relapse eligible for de-escalated adjuvant therapy.
引用
- Dieci MV, Conte P, Bisagni G, et al. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. Ann Oncol. 2019. PMID: 30657852. doi:10.1093/annonc/mdz007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。